The Future of Yuvezzi Eye Drops in Presbyopia, With John Hovanesian, MD скачать в хорошем качестве

The Future of Yuvezzi Eye Drops in Presbyopia, With John Hovanesian, MD

On January 28, 2026, the US Food and Drug Administration (FDA) announced its approval of Tenpoint Therapeutics’ Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults. The approval, which was spearheaded by positive data from the BRIO-I and BRIO-II phase 3 trials, marked Yuvezzi as the first and only combination eye drop approved for this indication. In addition to BRIO-I and BRIO-II, Yuvezzi underwent the largest and longest safety study for presbyopia eye drops, achieving miosis from 30 minutes to 10 hours with 1 drop daily. In an interview with John Hovanesian, MD, we discussed the process by which Yuvezzi achieved its approval and where the drug is going from here. “When we as clinicians think about Yuvezzi, we really have to think from the patients’ perspective, because this is a drug that’s new to us and we have a bit of unfamiliarity with prescribing it, recommending it, educating patients,” Hovanesian said. “And yet, patients are highly motivated. What patients want is to be young again. And of course, we can’t give them that, but we can give them a treatment that will allow them to function as though they were a little bit younger.” Read the full article here: https://www.hcplive.com/view/the-futu... Key Timestamps 00:00:01 Intro 00:00:11 Overview of Yuvezzi 00:01:41 How should clinicians view Yuvezzi? 00:02:43 Which patients would benefit most? 00:03:48 Regularity of use #ophthalmology #presbyopia #fdaapproval